Clinical Trial Update: A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase II/III trial is planned to compare IBB0979 plus topotecan versus topotecan alone in relapsed small cell lung cancer; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• IBB0979
• Topotecan (topotecan)

Snippet

Sponsor: SUNHO（China）BioPharmaceutical CO., Ltd. | Conditions: Small Cell Lung Cancer | Phase 2 | Status: NOT_YET_RECRUITING